Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 ...

Eli Lilly's Mounjaro clocked in ₹80 crore in September, second only to India’s leading brand of the month, GSK’s Augmentin, ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments ...

In January, when Sarah le Brocq signed up for a year’s supply of weight loss jab Mounjaro at £99 per month, it felt like a ...

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

Hims & Hears Health (HIMS) broke its uptrend that began in August at around $42. The stock peaked at over $60, only to close ...

Shares of weight-loss drug makers Novo Nordisk and Eli Lilly fell on Friday after U.S. President Donald Trump said that the ...